Channels • 2022 • Volume 6 • Number 2 Page 25 National Institutes of Health. (2020, December 10). Pre-Exposure Prophylaxis (PrEP) to Reduce HIV Risk. Pre-exposure Prophylaxis (PrEP) to Reduce HIV Risk | NIH: National Institute of Allergy and Infectious Diseases Ng'uni, T., Chasara, C., & Ndhlovu, Z. M. (2020). Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions. Frontiers in immunology, 11, 590780. https://doi.org/10.3389/fimmu.2020.590780 Picchio, G. R., Gulizia, R. J., Wehrly, K., Chesebro, B., Mosier, D. E. (1998). The Cell Tropism of Human Immunodeficiency Virus Type 1 Determines the Kinetics of Plasma Viremia i S n CID Mice Reconstituted with Human Peripheral Blood Leukocytes. Journal of Virology, 72(3), 2002-2009. https://doi.org/10.1128/JVI.72.3.2002-2009.1998 Pitisuttithum, P. & Marovich, M. A. (2020). Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges. Taylor Francis Online, 19(2), 133-142. https://doi.org/10.1080/14760584.2020.1718497 Rappocciolo, G., Piazza, P., Fuller, C. L., Reinhart, T. A., Watkins, S. C., Rowe, D. T., Jais, M., Gupta, P., & Rinaldo, C. R. (2006). DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes. PLoS pathogens, 2(7), e70. https://doi.org/10.1371/journal.ppat.0020070 Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018). New Vaccine Technologies to Combat Outbreak Situations. Frontiers in immunology, 9, 1963. https://doi.org/10.3389/fimmu.2018.01963 Shaw, G. M., & Hunter, E. (2012). HIV transmission. Cold Spring Harbor Perspectives in Medicine, 2(11), https://dx.doi.org/10.1101%2Fcshperspect.a006965 Siliciano, R. F. & Greene, W. C. (2011). HIV Latency. Cold Spring Harbor Perspectives in Medicine, 1(1). https://dx.doi.org/10.1101%2Fcshperspect.a007096 Sips, M., Krykbaeva, M., Diefenbach, T. J., Ghebremichael, M., Bowman, B. A., Dugast, A. S., Boesch, A. W., Streeck, H., Kwon, D. S., Ackerman, M. E., Suscovich, T. J., Brouckaert, P., Schacker, T. W., & Alter, G. (2016). Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies. Mucosal immunology, 9(6), 1584–1595. https://doi.org/10.1038/mi.2016.12
RkJQdWJsaXNoZXIy MTM4ODY=